COMBINATION OF AN MCL-1 INHIBITOR AND A STANDARD DRUG FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES, ITS USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT Russian patent published in 2023 - IPC A61K31/519 A61K31/55 A61P35/00 

FIELD: pharmacology.

SUBSTANCE: group of inventions relates to the field of pharmacology and medicine and is intended for the treatment of hematological malignancy. A combination for the treatment of hematological malignancy has been disclosed, which contains: (a) an inhibitor of Mcl-1, which is (2R)-2-{[(5Sa)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazine-1-yl)ethoxy] phenyl}-6-(5-fluorofuran-2-yl)thieno[2,3-d]pyrimidine-4-yl]oxy}-3-(2-{[1-(2,2,2- trifluoroethyl)-1H-pyrazole-5-yl]methoxy}phenyl)propane acid or (2R)-2-{[(5Sa)-5-{3- chloro-2-methyl-4-[2-(4-methylpiperazine-1-yl)ethoxy]phenyl}-6-(4- fluorophenyl)thieno[2,3-d]pyrimidine-4-il]oxy}-3-(2-{[2-(2- methoxyphenyl)pyrimidine-4-yl]methoxy}phenyl)propane acid, and (b) a second anticancer agent, where the second anticancer agent is selected from idarubicin, cytarabine and hypomethylating agents selected from decitabine and azacitidine, in synergistically effective amounts, for simultaneous, sequential or separate administration. In addition, the use of this combination for the preparation of a drug for the treatment of acute myeloid leukemia, myelodysplastic syndromes, acute lymphocytic leukemia and lymphoma is disclosed. Also disclosed are a drug, a method for the treatment of acute myeloid leukemia, myelodysplastic syndromes, acute lymphocytic leukemia and lymphoma, and a method for sensitizing a patient who (I) cannot be treated with at least one chemotherapy, or (ii) who has a relapse after chemotherapy treatment.

EFFECT: group of inventions provides synergistic pro-apoptotic activity with good tolerability in hematological cancer.

25 cl, 6 dwg, 7 tbl, 7 ex